Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is a prevalent, debilitating condition linked to significant morbidity and mortality. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated clinical benefits for COPD, the effect of tirzepatide on COPD outcomes remains to be fully elucidated.

This study utilized the TriNetX Global Collaborative Network to analyze data from adults with COPD who were prescribed tirzepatide between 1 January 2022, and 28 February 2025. Patients were divided into two groups: those prescribed tirzepatide and those receiving standard care (control group). Propensity score matching (PSM) was applied to balance covariates. The primary outcome was the risk of COPD exacerbations.

After PSM, the study included 12,110 patients (6,055 in each group). The tirzepatide group was associated with a lower risk of COPD exacerbations (HR, 0.77; 95% CI, 0.63-0.93) compared to the control group. Additionally, tirzepatide use was associated with a lower risk of mortality (HR, 0.52; 95% CI, 0.37-0.73), pneumonia (HR, 0.71; 95% CI, 0.59-0.86), and acute respiratory failure (HR, 0.59; 95% CI, 0.48-0.73).

Tirzepatide use was associated with a potentially reduced risk of COPD exacerbations, lower mortality, and a decreased incidence of pneumonia and acute respiratory failure. These findings should be interpreted with caution, given the inherent limitations of observational study designs, including the possibility of residual confounding and selection bias. The observed associations do not establish causality, and the clinical generalizability of these results remains uncertain. Prospective randomized controlled trials are warranted to confirm these preliminary findings.